ArticleInvestigative ophthalmology & visual science2006
Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma.
Article in Investigative ophthalmology & visual science, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- Primary vitreoretinal lymphoma: diagnosis, treatment, and prognosis-a review of current knowledge and future directions.Blood science (Baltimore, Md.) · 2025Review
- Next-Generation Sequencing of Vitreoretinal Lymphoma by Vitreous Liquid Biopsy: Diagnostic Potential and Genotype/Phenotype Correlation.Investigative ophthalmology & visual science · 2023Article
- Update in Molecular Testing for Intraocular Lymphoma.Cancers · 2022Review
- Review
- Clinical Features, Diagnosis, Management and Prognosis of Primary Intraocular Lymphoma.Frontiers in oncology · 2022Article
- Gene expression profiling of primary vitreoretinal lymphoma.Cancer science · 2020Article
- Cell-Permeable Bak BH3 Peptide Induces Chemosensitization of Hematologic Malignant Cells.Journal of oncology · 2020Article
- Cytologic and Molecular Diagnostics for Vitreoretinal Lymphoma: Current Approaches and Emerging Single-Cell Analyses.Frontiers in molecular biosciences · 2020Review
- Intraocular Biopsy and ImmunoMolecular Pathology for "Unmasking" Intraocular Inflammatory Diseases.Journal of clinical medicine · 2019Review
- Live AttenuatedFrontiers in immunology · 2019Article
- [Primary vitreoretinal lymphoma].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2018Article
- Primary central nervous system lymphoma: essential points in diagnosis and management.Medical oncology (Northwood, London, England) · 2017Review
- Intraocular lymphoma.International journal of ophthalmology · 2017Review
- Primary vitreoretinal lymphoma.Indian journal of ophthalmology · 2015Review
- High-resolution genomic copy number profiling of primary intraocular lymphoma by single nucleotide polymorphism microarrays.Cancer science · 2014Article
- Genetics of primary intraocular tumors.Ocular immunology and inflammation · 2012Review
- Vitreous diagnosis in neoplastic diseases.Mediators of inflammation · 2012Review
- Ocular involvement in patients with primary CNS lymphoma.Journal of neuro-oncology · 2011Article
- Diagnosis and management of primary intraocular lymphoma: an update.Clinical ophthalmology (Auckland, N.Z.) · 2007Article
- Biopsy techniques and yields in diagnosing primary intraocular lymphoma.International ophthalmology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
Abstract
purposePrimary intraocular lymphoma (PIOL) is a diffuse large B cell lymphoma that initially infiltrates the retina, vitreous, or optic nerve head, with or without central nervous system involvement. This study examined the expression of the bcl-2 t(14;18) translocation, the bcl-10 gene, and high expression of bcl-6 mRNA in PIOL cells.
methodsMicrodissection and PCR analysis were used to examine vitreous specimens in patients with PIOL for the presence of bcl-2 t(14;18) translocations, the bcl-10 gene, and expression of bcl-6 mRNA. A medical record review was also conducted to determine whether the bcl-2 t(14;18) translocation correlated with prognosis.
resultsForty of 72 (55%) PIOL patients expressed the bcl-2 t(14;18) translocation at the major breakpoint region. Fifteen of 68 (22%) patients expressed the translocation at the minor cluster region. The bcl-10 gene was detected in 6 of 26 (23%) patients, whereas 4 of 4 (100%) PIOL patients expressed higher levels of bcl-6 mRNA compared with inflammatory lymphocytes. An analysis of clinical outcome in 23 PIOL patients revealed no significant association between bcl-2 t(14;18) translocations and survival or relapse. However, patients with the translocation were significantly younger.
conclusionsPIOL has unique molecular patterns of bcl-2, bcl-10, and bcl-6 when compared with other systemic lymphomas. This study lays the foundation for future studies aimed at exploring the genotypic classification of PIOL based on the quantitative molecular framework of gene expression profiling, with the goal of providing useful adjuncts to the pathologic diagnosis of this complex disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.